According to the deal, GVK BIO will deliver a clinical candidate while Endo is responsible for the development and commercialization of the resulting product.
GVK BIO CEO Manni Kantipudi said Endo continues building discovery pipeline through external collaborations.
"This collaboration also confirms the value of our differentiated EDA concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates," Kantipudi added.
A new concept named Early Discovery Assets (EDA), launched by GVK BIO, formed basis for the collaboration.
Under the EDA, GVK Biosciences will discover a portfolio of discovery project assets, initially focused on pain and inflammation, and then collaborate with life science companies for co-development.
Endo drug discovery and early development senior vice president Dr. Sandeep Gupta said, "With their world class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients."